Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics

References

• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Singer EA, Golijanin DJ, Miyamoto H, et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother. 2008 02 01;9(2):211–228. DOI:10.1517/14656566.9.2.211.
   PubMed Web of Science ®Google Scholar
• Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1. J Natl Compr Canc Netw. 2016 Jan;14(1):19–30. PubMed PMID: 26733552.
   PubMed Web of Science ®Google Scholar
• Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20;25(12):1596–1605. PubMed PMID: 17404365. DOI:10.1200/JCO.2006.10.1949
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293–297.
   Google Scholar
• Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9 Suppl 1: S3–8. PubMed PMID: 17387371; PubMed Central PMCID: PMCPMC1831539.
   PubMedGoogle Scholar
• Petrylak DP. Current state of castration-resistant prostate cancer. Am J Manag Care. 2013 Dec;19(18 Suppl):s358–65. PubMed PMID: 24494690; eng.
   PubMed Web of Science ®Google Scholar
• Stein M, Patel N, Bershadskiy A, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer [Invited Review]. Asian J Androl. 2014 May 1;16(3):387–400. DOI:10.4103/1008-682x.129133.
   PubMed Web of Science ®Google Scholar
• Woolf TF, Jordan RA. Basic concepts in drug metabolism: part I. J Clin Pharmacol. 1987 Jan;27(1):15–17. PubMed PMID: 3316300.
   PubMed Web of Science ®Google Scholar
• Jordan RA, Woolf TF. Basic concepts in drug metabolism: part II. J Clin Pharmacol. 1987 Feb;27(2):87–90. PubMed PMID: 3316305.
   PubMed Web of Science ®Google Scholar
• Eckstein N, Haas B. Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer. Eur J Clin Pharmacol. 2014 Jul;70(7):791–798. DOI:10.1007/s00228-014-1682-1. PubMed PMID: 24756149; PubMed Central PMCID: PMCPMC4148177.
   PubMed Web of Science ®Google Scholar
• Cockshott ID. Clinical pharmacokinetics of goserelin. Clin Pharmacokinet. 2000 Jul;39(1):27–48. DOI:10.2165/00003088-200039010-00003. PubMed PMID: 10926349.
   PubMed Web of Science ®Google Scholar
• Chrisp P, Sorkin EM. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging. 1991 Nov-Dec;1(6):487–509. PubMed PMID: 1794035.
   PubMedGoogle Scholar
• Bubley GJ. Is the flare phenomenon clinically significant? Urology. 2001 Aug;58(2 Suppl 1):5–9. PubMed PMID: 11502435.
   PubMedGoogle Scholar
• Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009 Jun 01;115(11):2388–2399. doi:10.1002/cncr.24283. PubMed PMID: 19399748.
   PubMed Web of Science ®Google Scholar
• Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs. 2009 Oct 01;69(14):1967–1976. doi:10.2165/10484080-000000000-00000. PubMed PMID: 19747011.
   PubMed Web of Science ®Google Scholar
• Klotz L. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer. PubMed PMID: 26513436 Expert Opin Drug Metab Toxicol. 2015;1111:1795–1802. 10.1517/17425255.2015.1085506
   PubMed Web of Science ®Google Scholar
• Virgo KS, Basch E, Loblaw DA, et al. Second-line hormonal therapy for men with chemotherapy-naive, castration-resistant prostate cancer: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol. 2017 Jun 10;35(17):1952–1964. PubMed PMID: 28441112. DOI:10.1200/JCO.2017.72.8030
   PubMed Web of Science ®Google Scholar
• Mahler C, Verhelst J, Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet. 1998 May;34(5):405–417. DOI:10.2165/00003088-199834050-00005. PubMed PMID: 9592622.
   PubMed Web of Science ®Google Scholar
• Androcur (cyproterone) [product monograph]. Toronto, Ontario, Canada: bayer Inc; February 2011. [cited 2017 Aug]. Available from: http://omr.bayer.ca/omr/online/androcur-pm-en.pdf
   Google Scholar
• Kuhnz W, Kulmann H, Fuhrmeister A. Investigation into the age-dependence of the pharmacokinetics of cyproterone acetate in healthy male volunteers. Eur J Clin Pharmacol. 1997;53(1): 75–80. PubMed PMID: 9349934.
   PubMed Web of Science ®Google Scholar
• Cyproterone acetate [package insert]. Cipla life sciences (Pty) Ltd.. Bellville, RSA; 2002 cited 2017 Jul. Available from: http://www.cipla.co.za/wp-content/uploads/2013/10/sep_cipla-cyproterone-50mg.pdf
   Google Scholar
• Kunath F, Grobe HR, Rucker G, et al. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review. BJU Int. 2015 Jul;116(1):30–36. PubMed PMID: 25523493. DOI:10.1111/bju.13026
   PubMed Web of Science ®Google Scholar
• McCutcheon SB. Enzalutamide: a new agent for the prostate cancer treatment armamentarium. J Adv Pract Oncol. 2013 May;4(3):182–185. PubMed PMID: 25031999; PubMed Central PMCID: PMCPMC4093421.
   PubMedGoogle Scholar
• Enzalutamide [package insert]. Astellas Pharma US, Inc.. Northbrook, IL; 2012 cited 2017 Aug. Available from: https://www.us.astellas.com/docs/12A005-ENZ-WPI.PDF
   Google Scholar
• Schulz M, Schmoldt A, Donn F, et al. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol. 1988;34(6):633–636. PubMed PMID: 3169114.
   PubMed Web of Science ®Google Scholar
• Brogden RN, Flutamide CP. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer. Drugs Aging. 1991 Mar;1(2):104–115. PubMed PMID: 1794008.
   PubMedGoogle Scholar
• Shet MS, McPhaul M, Fisher CW, et al. Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298–1303. PubMed PMID: 9351907.
   PubMed Web of Science ®Google Scholar
• Bicalutamide [package insert]. TEVA Pharmaceutical Ind. Ltd. Jerusalem, Israel; 2009 cited 2017 Jul. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/076932s000lbl.pdf
   Google Scholar
• Cockshott ID. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13): 855–878. PubMed PMID: 15509184.
   PubMed Web of Science ®Google Scholar
• Creaven PJ, Pendyala L, Tremblay D. Pharmacokinetics and metabolism of nilutamide. Urology. 1991;37(2 Suppl): 13–19. PubMed PMID: 1992598.
   PubMed Web of Science ®Google Scholar
• Nilutamide [package insert]. ANI Pharmaceuticals, Inc. Baudette, MN; 2015 cited 2017 Jul. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207631Orig1s000lbl.pdf
   Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494–1503. PubMed PMID: 22266222; PubMed Central PMCID: PMCPMC3306502. DOI:10.1158/0008-5472.CAN-11-3948
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013 Oct 01;31(28):3525–3530. PubMed PMID: 24002508; PubMed Central PMCID: PMCPMC3782148. DOI:10.1200/JCO.2013.50.1684
   PubMed Web of Science ®Google Scholar
• Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. 2008 Jun;112(11):2393–2400. PubMed PMID: 18383517; PubMed Central PMCID: PMCPMC3359896. DOI:10.1002/cncr.23473
   PubMed Web of Science ®Google Scholar
• Hongo H, Kosaka T, Mizuno R, et al. Should we try antiandrogen withdrawal in castration-resistant prostate cancer patients? Insights from a retrospective study. Clin Genitourin Cancer. 2016 Dec;14(6):e569–e573. PubMed PMID: 27036975. DOI:10.1016/j.clgc.2016.02.014
   PubMedGoogle Scholar
• Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol. 1987 May;137(5):959. PubMed PMID: 3573195.
   PubMed Web of Science ®Google Scholar
• Han CS, Patel R, Kim IY. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):967–975. DOI:10.1517/17425255.2015.1041918. PubMed PMID: 25936418.
   PubMed Web of Science ®Google Scholar
• Abiraterone acetate [package insert]. Janssen Biotech, Inc. Horsham, PA; 2011 cited 2017 Aug. Available from: https://www.zytiga.com/shared/product/zytiga/zytiga-prescribing-information.pdf
   Google Scholar
• Harris KA, Weinberg V, Bok RA, et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002 Aug;168(2):542–545. PubMed PMID: 12131305.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152–160. PubMed PMID: 25601341. DOI:10.1016/S1470-2045(14)71205-7
   PubMed Web of Science ®Google Scholar
• Turo R, Smolski M, Esler R, et al. Diethylstilboestrol for the treatment of prostate cancer: past, present and future. Scand J Urol. 2014 Feb;48(1):4–14. PubMed PMID: 24256023. DOI:10.3109/21681805.2013.861508
   PubMed Web of Science ®Google Scholar
• Roy D, Bernhardt A, Strobel HW, et al. Catalysis of the oxidation of steroid and stilbene estrogens to estrogen quinone metabolites by the beta-naphthoflavone-inducible cytochrome P450 IA family. Arch Biochem Biophys. 1992 Aug 01;296(2):450–456. PubMed PMID: 1632637.
   PubMed Web of Science ®Google Scholar
• Epe B, Schiffmann D, Metzler M. Possible role of oxygen radicals in cell transformation by diethylstilbestrol and related compounds. Carcinogenesis. 1986 Aug;7(8):1329–1334. PubMed PMID: 3015447.
   PubMed Web of Science ®Google Scholar
• Liehr JG, DaGue BB, Ballatore AM, et al. Diethylstilbestrol (DES) quinone: a reactive intermediate in DES metabolism. Biochem Pharmacol. 1983 Dec 15;32(24):3711–3718. PubMed PMID: 6661246.
   PubMed Web of Science ®Google Scholar
• Chandrasekar T, Yang JC, Gao AC, et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015 Jun;4(3):365–380. PubMed PMID: 26814148; PubMed Central PMCID: PMCPMC4708226.
   PubMed Web of Science ®Google Scholar
• Chandrasekar T, Yang JC, Gao AC, et al. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015 Sep 01;13:206. PubMed PMID: 26329698; PubMed Central PMCID: PMCPMC4556222. DOI:10.1186/s12916-015-0457-6
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015 Aug 20;373(8):737–746. PubMed PMID: 26244877; PubMed Central PMCID: PMCPMC4562797. DOI:10.1056/NEJMoa1503747
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1163–1177. PubMed PMID: 26719232; PubMed Central PMCID: PMCPMC4800035. DOI:10.1016/S0140-6736(15)01037-5
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct;13(10):983–992. PubMed PMID: 22995653. DOI:10.1016/S1470-2045(12)70379-0
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017 Jul 27;377(4):352–360. PubMed PMID: 28578607. DOI:10.1056/NEJMoa1704174
   PubMed Web of Science ®Google Scholar